This mechanism could explain the contribution of SARS-CoV-2 entry and pathogenesis of CRS, IL-6 release, and that the potential role of TCZ in the management of COVID-19 could be mediated through its inhibitory effect on sIL-6R. Here, IL6 is linked to congenital rubella syndrome.